Immediate Impact
56 standout
Citing Papers
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
2025 Standout
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Works of Stephen Harnicar being referenced
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <em>NTRK</em>, <em>ROS1</em>, and <em>ALK</em> fusion-positive solid tumors
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Stephen Harnicar | 47 | 13 | 64 | 97 | 95 | 17 | 285 | |
| Akane Sakaguchi | 138 | 1 | 56 | 109 | 100 | 15 | 322 | |
| Christelle Orlando | 119 | 1 | 48 | 94 | 59 | 24 | 283 | |
| Dimitrios Zgouras | 42 | 114 | 113 | 57 | 12 | 304 | ||
| Jeanette Dickson | 18 | 39 | 98 | 60 | 12 | 289 | ||
| Karine Juvin | 67 | 2 | 32 | 85 | 69 | 18 | 317 | |
| Ghislaine Dufaître | 20 | 49 | 39 | 135 | 15 | 247 | ||
| Laurel A. Menapace | 81 | 26 | 202 | 113 | 16 | 314 | ||
| María Borrell | 129 | 1 | 62 | 62 | 48 | 21 | 319 | |
| Anastasia Laudisi | 36 | 62 | 41 | 27 | 13 | 330 | ||
| Michael Sproule | 28 | 17 | 112 | 64 | 14 | 333 |
All Works
Login with ORCID to disown or claim papers
Loading papers...